Systemic sclerosis

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…

This study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …

This study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…

This study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…

This trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…

This study tests whether new investigational drugs can improve lung function in people with scleroderma-related lung scarring. About 400 adults with this condition will receive either the study drug or a placebo for 52 weeks. The main goal is to see if the drug helps preserve or …

This early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrol…

This early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …

This study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…

This early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…

This early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…

This study tests whether temporarily stopping methotrexate for 2 weeks after receiving a pneumonia vaccine (PCV20) helps the vaccine work better in adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus. About 192 participants with stable, low disease activi…

This early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…

This study tests whether transplanting healthy gut bacteria can relieve constipation and bloating in people with systemic sclerosis, an autoimmune disease that often affects the digestive tract. Participants will receive the bacteria either as capsules or as a retention enema. Th…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This early-stage trial tests a new drug called TOP-N53, applied directly to finger ulcers in people with systemic sclerosis (scleroderma). The main goal is to check safety and see if it improves pain and blood flow. Fifteen participants will receive either the drug or a placebo o…

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…

This early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …

This early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…

This early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…

This study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments (like mycophenolate) for people with systemic sclerosis (scleroderma) who also have lung scarring. The trial will enroll 86 adults and follow them for 56 weeks, measuri…

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…

This study tests a drug called nemolizumab in 162 adults with systemic sclerosis, a disease that causes skin thickening and can harm internal organs. Participants receive either nemolizumab or a placebo as a shot under the skin for 52 weeks. The main goal is to see if the drug re…

This study tests whether adding two immune-targeting drugs (belimumab and rituximab) to standard mycophenolate can improve skin fibrosis in people with early diffuse systemic sclerosis. Thirty adults with recent-onset disease will receive either the combo or placebo injections fo…

This study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfen…

This early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…

This early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects with…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This study tests whether infusions of stem cells from donated umbilical cords are safe and can help people with systemic sclerosis, a rare disease that causes skin hardening and organ damage. 18 adults with severe disease will receive either the stem cells or a placebo. Researche…

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…

This early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the d…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack the disease. The main …

This phase 2 trial tests whether injecting a patient's own cultured fat stem cells into stubborn finger ulcers can help them heal. The study includes 32 adults with scleroderma who have at least one ulcer that hasn't healed with standard care. Half get stem cell injections, half …

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…

This study tests whether itacitinib is safe and effective for adults with systemic sclerosis, a disease that causes skin thickening and organ damage. About 74 participants with early or active disease will receive the drug or a placebo for one year. The main goal is to see if it …

This phase 2 trial tests whether sildenafil, a drug used for pulmonary hypertension, can help people with scleroderma who have mildly elevated lung pressures. Thirty participants will receive either sildenafil or a placebo for 4 months. The main goal is to see if the drug improve…

This study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…

This trial tests a one-time treatment using a patient's own immune cells, engineered to target and destroy B cells, which drive autoimmune diseases like lupus, scleroderma, and myositis. 24 adults with active disease will receive the therapy after a short chemotherapy. The main g…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…

This early-stage trial tests a new type of CAR-T cell therapy in 11 children with severe rheumatic diseases like juvenile dermatomyositis and arthritis that haven't improved with standard treatments. The therapy uses specially engineered immune cells to target and calm the overac…

This early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…

This early-stage trial is testing a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe autoimmune diseases like systemic sclerosis and Sjogren's syndrome…

This early-phase trial tests whether injecting stem cells (mesenchymal stromal cells) into the hand and forearm muscles can safely help heal painful finger ulcers in people with scleroderma. The study includes 20 participants whose ulcers have not improved with standard treatment…

This study is testing a new blood test (the HMEC test) to see if it can better identify which patients with thrombotic microangiopathy (TMA) have a specific immune system problem driving their disease. TMA is a severe condition that damages kidneys and the brain. The researchers …

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participa…

This study tests whether diosmin, a citrus-based supplement, can safely heal open sores on the fingers of people with scleroderma. About 45 adults with at least one active digital ulcer will take either diosmin or a placebo for 8 weeks. Researchers will track ulcer healing, pain,…

This study compares three different diets to see which one best reduces bloating and other stomach symptoms in people with systemic sclerosis (scleroderma). Sixty participants will follow one of three diets for six weeks: a low-FODMAP diet, a diet that removes foods harmful to th…

This study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…

This study tests whether injecting sodium thiosulfate directly into painful calcium deposits (calcinosis) can shrink them and ease symptoms. Twenty adults with scleroderma, dermatomyositis, or mixed connective tissue disease will receive ultrasound-guided injections. The main goa…

This study tests an oral pill called treprostinil in 30 adults with severe Raynaud's phenomenon that hasn't improved with usual therapies. Raynaud's causes fingers and toes to change color and become painful when cold or stressed. Participants will take the pill three times daily…

This study tests if a person's own fat-derived cells can improve hand function in systemic sclerosis, a disease that causes skin thickening and stiffness. 48 adults with hand problems will either get injections of these cells into their fingers or receive standard care. The goal …

This study tests whether a wearable device called Apollo Neuro can reduce fatigue and Raynaud's attacks in people with systemic sclerosis (scleroderma). The device delivers gentle vibrations to the skin. 160 participants will wear it daily for 6 weeks and report their symptoms. T…

This study is testing a structured exercise program called BETY, which focuses on the whole person (body, mind, and social factors), in 48 children and adults with scleroderma. Participants will either do the BETY program for 3 months or follow a home exercise routine. The goal i…

This study tests whether a lotion containing 1% hemp extract (CBD) plus 10% urea can relieve itching, improve skin moisture, and help sleep in people with scleroderma. About 36 adults with chronic itching will use both the CBD lotion and a plain urea lotion at different times to …

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This study investigates whether systemic sclerosis, a rare autoimmune disease, changes the community of bacteria living in the mouth. Researchers will collect dental plaque samples from 30 participants—some with scleroderma and some without—to compare the types and functions of o…

This study aims to understand the cellular and molecular mechanisms behind systemic sclerosis (SSc), a rare autoimmune disease that causes skin and organ fibrosis. Researchers will collect skin punch biopsies and blood samples from 500 participants, including those with SSc and h…

This study is testing a new device called ADHELASKIN to see if it can measure skin stiffness more accurately than the current method (feeling the skin by hand) in people with systemic sclerosis (scleroderma). The study will compare 100 participants: those with scleroderma and hea…

This study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors d…

This study is testing a new, non-invasive imaging technique called spatial frequency domain imaging (SFDI) to measure skin thickness in people with scleroderma. Currently, doctors use a subjective pinch test, but SFDI uses light scattering to measure collagen in the skin more acc…

This study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …

This study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…

This study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…

This study aims to find better ways to detect lung scarring (interstitial lung disease) early in people with connective tissue diseases like scleroderma or rheumatoid arthritis. Researchers will analyze tiny particles in the blood called extracellular vesicles and use AI to exami…

This study looks at whether a simple, non-invasive scalp exam called trichoscopy can help predict how severe systemic scleroderma is and whether it affects internal organs. Researchers will compare scalp images from 200 scleroderma patients and healthy volunteers. The goal is to …

This study aims to better understand rare forms of inflammatory arthritis, including those linked to other autoimmune diseases or cancer immunotherapy. Researchers will analyze joint tissue samples from 100 adults to compare the immune cells and molecules involved. The goal is to…

This study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…

This study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …

This study aims to develop a better way to measure calcium deposits under the skin in people with scleroderma. Researchers will use CT scans and special software to see if these measurements match how patients report their symptoms. About 56 adults with scleroderma and calcium de…

This study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…

This study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…

This study looks at skin cells called fibroblasts from people with scleroderma and healthy volunteers. Researchers want to find which genes are turned on or off in these cells, especially those linked to aging and inflammation. The goal is to better understand what causes the dis…

This study looks at 20 adults with systemic scleroderma who have a family history of the disease. Researchers will describe their symptoms and progression to find clues about how the disease works and identify markers that could lead to new treatments. The goal is to learn more, …

This observational study aims to uncover why systemic sclerosis (SSc) develops and worsens. Researchers will analyze blood, skin, and DNA from 150 patients in Sweden to find markers linked to disease activity and progression. The goal is to improve diagnosis and identify new trea…

This registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…

This study looks at skin and blood samples from 40 people with systemic sclerosis (scleroderma) to understand why the disease causes scarring. Researchers will analyze individual cells to see how different types of fibroblasts and immune cells behave. The goal is to find new clue…

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study is testing whether artificial intelligence (AI) can better detect a serious lung condition called pulmonary arterial hypertension (PAH) in people with scleroderma. Researchers will compare AI algorithms to traditional screening methods in 350 patients across multiple h…

This study looks at gut bacteria in people with systemic sclerosis (a chronic autoimmune disease) and compares them to healthy volunteers. Researchers will collect stool samples from 60 patients over 7 months and one sample from healthy controls. The goal is to understand how gut…

This study aims to translate and test a questionnaire called PASTUL, which helps people with scleroderma assess their own skin thickness. Researchers will enroll 50 Turkish-speaking adults with scleroderma to see if the Turkish version is accurate and reliable. The goal is to giv…

This study looks at how biological, psychological, and social factors affect physical performance in people with scleroderma. Researchers will test 50 children and adults using simple tasks like walking, stair climbing, and standing up from a chair. The goal is to find better way…

This study looks at how scleroderma affects chewing and swallowing in both children and adults. Researchers will use questionnaires and physical tests to measure these functions and understand the overall well-being of participants. The goal is to find better tools for assessing …

This study follows 500 adults with systemic sclerosis (scleroderma) for up to 5 years. Researchers will collect blood samples, and in some volunteers, skin or lung samples, to track how the disease changes over time. The goal is to better understand the natural course of this rar…